Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Free Cash Flow (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Free Cash Flow for 16 consecutive years, with $877000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 150.93% to $877000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $7.4 million, a 780.47% increase, with the full-year FY2024 number at -$1.2 million, down 109.84% from a year prior.
  • Free Cash Flow was $877000.0 for Q3 2025 at Harvard Bioscience, down from $2.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $4.1 million in Q3 2023 to a low of -$2.5 million in Q1 2022.
  • A 5-year average of $877947.4 and a median of $877000.0 in 2025 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 377.31% in 2022, then soared 1901.93% in 2023.
  • Harvard Bioscience's Free Cash Flow stood at -$241000.0 in 2021, then soared by 1114.11% to $2.4 million in 2022, then skyrocketed by 42.1% to $3.5 million in 2023, then crashed by 59.0% to $1.4 million in 2024, then tumbled by 38.41% to $877000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Free Cash Flow are $877000.0 (Q3 2025), $2.7 million (Q2 2025), and $2.5 million (Q1 2025).